Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Novo Nordisk

Status: Completed

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: Semaglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT06351748

U1111-1296-3151 (Other Identifier)

NN9535-7877

Details and patient eligibility

About

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Enrollment: 34,238 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female participants aged greater than or equal to (≥) 18 years on index date
• Participants with diagnosis of T2DM prior to or on index date
• Participants with initiation of semaglutide OW for the first time within the identification period

Exclusion criteria

• Participants with diagnosis of type 1 diabetes prior to or on index date
• Participants who were pregnant within 36 months prior to or on index date
• Participants who participated in any clinical trials within 36 months prior to or on index date which could be identified from medical records

Trial design

34,238 participants in 1 patient group

Participants with T2DM

Description:

Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023.

Treatment:

Drug: Semaglutide